Inhalation Sciences: Another major sale, plus 2 systems shipped in 2 months, CEO speaks

  • 13 december, 2018
  • 13:29

Inhalation Sciences’ recent announcement of a 2 MSEK order from a leading inhalation company is the third major order announced since the appointment of Lena Heffler as new CEO, on May 7. How does she see the year ahead for ISAB? And how will it keep up the momentum?

Since starting as ISAB’s new CEO on May 7 Lena Heffler has brought three major orders into the company, including ISAB’s first shipment to China. When appointed CEO she stated: ”Inhalation Sciences is in an exciting phase, with many customer dialogues ongoing and a commercial breakthrough within reach.” How does she feel about that statement now?

“I hold with it entirely,” says Heffler. “I always remind people: our customers aren’t just ‘any’ customers—they’re leaders. The best in the field. We’re proud to work with them. And with every discussion we have our data really does speak for itself. The precision and control we offer lets pharma companies eliminate error from the beginning, and cut drug development time. I believe absolutely in our vision of PreciseInhale® becoming the standard R&D tool for inhalation research worldwide. We’re winning that argument system by system”.

What lies ahead?

“As I’ve said before we have ongoing discussions that we are confident will lead to increased sales. To prepare for these future sales operationally we have developed IQ, OQ and PQ onsite test protocols to guarantee the quality of each and every PreciseInhale® for customers. And we’re developing a comprehensive package of training options so that customers can be sure they’re getting all the scientific, operational and strategic benefits out of their system and its modules.”

Regulatory opportunities

“We are especially pleased that our unique in vitro module, DissolvIt ® was included in our latest purchase. There is no other system we know of on the market that delivers in vitro lung data early on that so closely matches in vivo data. It reduces risk in early-stage selection of drug candidates, saving pharma companies significant time and money. We believe we could see early-stage dissolution testing become a mandatory part of all pharma and toxicological testing in the future—currently there in on other system available that can actually deliver that data.”